News & Updates

IVIg therapy gains the upper hand in ProDERM

08 Jun 2021 by

Results of the phase III, placebo-controlled ProDERM trial reported at EULAR 2021 showed significant efficacy and acceptable safety for immunoglobulin therapy given intravenously (IVIg) to patients with dermatomyositis – a systemic autoimmune disease marked by progressive proximal muscle weakness and a distinctive skin rash.

IVIg therapy gains the upper hand in ProDERM

08 Jun 2021

No increased risk of COVID-19 in patients with RMDs

07 Jun 2021 by

There is no evidence so far that patients with rheumatic and musculoskeletal diseases (RMDs) are at an increased risk of COVID-19 or have a worse prognosis, says a rheumatology expert at EULAR 2021.

No increased risk of COVID-19 in patients with RMDs

07 Jun 2021

Fenebrutinib disappoints in systemic lupus erythematosus

03 Jun 2021

The noncovalent, highly selective inhibitor of Bruton’s tyrosine kinase fenebrutinib is safe in patients with systemic lupus erythematosus but falls short of improving disease activity, according to the results of a phase II trial.

Fenebrutinib disappoints in systemic lupus erythematosus

03 Jun 2021

Gastroprotective agents strike out on ILD prevention in systemic sclerosis

31 May 2021

Use of gastroprotective and promotility agents does not appear to reduce the incidence of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), a study reports.

Gastroprotective agents strike out on ILD prevention in systemic sclerosis

31 May 2021

Smoking causes more problems in fibromyalgia patients

31 May 2021

Tobacco use spells trouble for patients with fibromyalgia, contributing to greater pain and increased severity of other symptoms, as shown in a study.

Smoking causes more problems in fibromyalgia patients

31 May 2021

FORWARD: Sprifermin yields durable structural improvements in knee OA

27 May 2021 by

In patients in knee osteoarthritis (OA), the disease-modifying OA drug sprifermin produces a favourable change in articular cartilage, which is sustained for more than 3 years after treatment, according to 5-year data from the FORWARD* trial.

FORWARD: Sprifermin yields durable structural improvements in knee OA

27 May 2021

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021 by

The high-affinity, humanized, anti-interleukin-23-p19 monoclonal antibody tildrakizumab showed durable efficacy and safety for the treatment of chronic plaque psoriasis, according to the week 256 findings of the reSURFACE 1 trial.

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021

Polypharmacy in RA tied to several comorbidities

24 May 2021

Polypharmacy occurs generally in patients with rheumatoid arthritis, with a prevalence of 67.9 percent, and has shown a relationship with a number of comorbidities, according to a study. The researchers stress the need for solutions in managing this problem.

Polypharmacy in RA tied to several comorbidities

24 May 2021

Dapirolizumab pegol for systemic lupus shows efficacy signal

19 May 2021

Patients with systemic lupus erythematosus (SLE) appear to exhibit improvements with dapirolizumab pegol in a phase IIb trial, which, however, did not meet its primary endpoint.

Dapirolizumab pegol for systemic lupus shows efficacy signal

19 May 2021

Low disease activity key to reducing adverse pregnancy outcomes in women with SLE

19 May 2021

Adverse pregnancy outcomes more frequently occur among women with systemic lupus erythematosus (SLE), results of a study have shown. SLE patients are then advised to delay pregnancy until they achieve Lupus Low Disease Activity State (LLDAS) and to closely monitor pregnancies with the lowest possible dose of corticosteroid (CS).

Low disease activity key to reducing adverse pregnancy outcomes in women with SLE

19 May 2021

News & Updates

Filter by Specialty:

Specialty:

IVIg therapy gains the upper hand in ProDERM

IVIg therapy gains the upper hand in ProDERM

No increased risk of COVID-19 in patients with RMDs

No increased risk of COVID-19 in patients with RMDs

Fenebrutinib disappoints in systemic lupus erythematosus

Fenebrutinib disappoints in systemic lupus erythematosus

Gastroprotective agents strike out on ILD prevention in systemic sclerosis

Gastroprotective agents strike out on ILD prevention in systemic sclerosis

Smoking causes more problems in fibromyalgia patients

Smoking causes more problems in fibromyalgia patients

FORWARD: Sprifermin yields durable structural improvements in knee OA

FORWARD: Sprifermin yields durable structural improvements in knee OA

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

Polypharmacy in RA tied to several comorbidities

Polypharmacy in RA tied to several comorbidities

Dapirolizumab pegol for systemic lupus shows efficacy signal

Dapirolizumab pegol for systemic lupus shows efficacy signal

Low disease activity key to reducing adverse pregnancy outcomes in women with SLE

Low disease activity key to reducing adverse pregnancy outcomes in women with SLE